The effectiveness of  Clostridium botulinum  toxin A (Dysport ® , AbobotulinumtoxinA) in the management of temporomandibular dysfunction (TMD) and a small number of other maxillofacial conditions; an open cohort study | Zendy

White S. | Zendy; Ahmed B. | Zendy; Ondhia A. | Zendy

Premium

The effectiveness of Clostridium botulinum toxin A (Dysport ® , AbobotulinumtoxinA) in the management of temporomandibular dysfunction (TMD) and a small number of other maxillofacial conditions; an open cohort study

Author(s) -

White S.,

Ahmed B.,

Ondhia A.

Publication year - 2018

Publication title -

oral surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.156

H-Index - 11

eISSN - 1752-248X

pISSN - 1752-2471

DOI - 10.1111/ors.12338

Subject(s) - medicine , retrospective cohort study , cohort , botulinum toxin , cohort study , open bite , surgery , dentistry , malocclusion

Aim To examine the effectiveness of Botulinum Toxin Type A (Dysport ® ) in treating TMD and a small number of other maxillofacial conditions in our department. The secondary aim was to identify any predictors of outcome. Methods A retrospective open cohort study[1][Dekkers OM, 2012]; data abstraction from 38 case files. Results The effectiveness of Dysport ® in treating TMD lies between 60% and 79%. Sixty‐nine per cent of patients who obtained benefit received repeat treatment. Conclusions Our findings suggest Dysport ® is a safe, well‐tolerated and effective treatment for TMD and Masseteric hypertrophy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research